Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Company Overview - Aoyang Health's closing price on August 12 was 4.22 yuan, down 1.63%, with a rolling PE ratio of 114.10 times and a total market value of 3.231 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with main products including medical services and pharmaceutical logistics [1] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Financial Performance - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a gross margin of 15.09% [2] - The company's PE ratio (TTM) is 114.10, while the industry average is 48.17 and the industry median is 63.54 [2] Industry Comparison - Aoyang Health ranks 39th in the medical services industry based on PE ratio, which has an average of 48.17 and a median of 63.54 [1] - The company has been recognized in various awards, including being ranked 32nd in the non-public hospital top 100 list and 2nd among county-level non-public hospitals in China [1]

澳洋健康最新一期业绩显示，截至2025一季报，公司营业总收入4.52亿元、同比减少22.27%，归属净利 润1849.92万元，同比减少39.82%，扣非净利润1755.00万元，同比减少37.00%，流动比率0.660、速动比 率0.562、资产负债率93.46%。 天眼查商业履历信息显示，江苏澳洋健康产业股份有限公司，成立于2001年，位于苏州市，是一家以从 事化学纤维制造业为主的企业。企业注册资本76573.236万人民币，实缴资本5000万人民币。公司法定 代表人为沈学如。 金融界消息 截至2025年8月11日收盘，澳洋健康（002172）报收于4.29元，上涨0.23%，换手率5.33%， 成交量40.80万手，成交金额1.73亿元。 资金流向方面，今日主力资金净流出1026.85万元，占比成交额5.94%。其中，超大单净流出397.24万 元、占成交额2.3%，大单净流出629.60万元、占成交额3.64%，中单净流出流入12.20万元、占成交额 0.07%，小单净流入1014.64万元、占成交额5.87%。 通过天眼查大数据分析，江苏澳洋健康产业股份有限公司共对外投资了12家企业，参与招投标项目 ...

Group 1 - The high-pressure oxygen chamber concept sector rose by 1.57%, ranking 6th among concept sectors, with 9 stocks increasing in value [1] - Leading stocks in the high-pressure oxygen chamber sector included Tiebian Heavy Industry, Sanying Medical, and Weiao Co., which rose by 6.76%, 4.56%, and 2.41% respectively [1] - The sector experienced a net inflow of 0.17 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.54 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, Aoyang Health, and Sanying Medical were 10.77%, 7.40%, and 4.90% respectively [3] - The trading turnover rates for the leading stocks in the high-pressure oxygen chamber sector were as follows: Tiebian Heavy Industry at 4.43%, Sanying Medical at 2.70%, and Aoyang Health at 7.82% [3] - Stocks that experienced declines included Jinling Pharmaceutical and International Medicine, which fell by 1.76% and 0.92% respectively [1][4]

公司全资子公司张家港澳洋医院有限公司，拟以自有资金向其全资子公司张 家港澳洋护理院有限公司（以下简称"澳洋护理院"）增资，增资金额为人民币 民币2,200万元。 表决结果：同意9票，反对0票，弃权0票。 上述议案的详细内容，请见同日《证券时报》或公司指定信息披露网站（巨 潮资讯网 www.cninfo.com.cn）。 江苏澳洋健康产业股份有限公司 董事会 二〇二五年八月五日 证券代码：002172 证券简称：澳洋健康 公告编号：2025-25 江苏澳洋健康产业股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第五次会议于 2025 年 7 月 24 日以通讯方式发出会议通知，于 2025 年 际出席会议董事 9 名。会议由公司董事长沈学如先生主持，符合《公司法》及公 司《章程》的有关规定。公司监事及高管列席了会议。会议经认真审议，通过如 下议案： 一、审议通过《关于全资子公司增资的议案》 第九届董事会第五次会议决议公告 -1- ...

Core Viewpoint - Aoyang Health's stock price increased by 3.41% on August 4, closing at 4.25 yuan, with a trading volume of 700,702 hands and a transaction amount of 293 million yuan [1] Company Overview - Aoyang Health operates in the healthcare services industry, with its main business segments being healthcare services and pharmaceutical logistics [1] - In the 2024 annual report, the revenue distribution shows that healthcare services account for 50.49% and pharmaceutical logistics account for 49.51% of the total revenue [1] Recent Developments - On the evening of August 4, Aoyang Health announced that its ninth board meeting approved a proposal regarding the capital increase of its wholly-owned subsidiary [1]

每经AI快讯，澳洋健康（SZ 002172，收盘价：4.25元）8月4日晚间发布公告称，江苏澳洋健康产业股 份有限公司于2025年8月4日召开第九届董事会第五次会议，审议通过了《关于全资子公司增资的议 案》。公司全资子公司张家港澳洋医院有限公司，拟以自有资金向其全资子公司张家港澳洋护理院有限 公司增资，增资金额为人民币1700万元。本次增资完成后，澳洋护理院的注册资本由人民币500万元变 更为人民币2200万元。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 2024年1至12月份，澳洋健康的营业收入构成为：医疗服务占比50.49%，医药物流占比49.51%。 截至发稿，澳洋健康市值为33亿元。 ...

Group 1 - The company, Aoyang Health, announced that its ninth fifth board meeting was held on August 4, 2025, to discuss the proposal for capital increase of its wholly-owned subsidiary [2] - For the year 2024, Aoyang Health's revenue composition was reported as follows: medical services accounted for 50.49%, while pharmaceutical logistics made up 49.51% [2]

格隆汇8月4日丨澳洋健康(002172.SZ)公布，公司于2025年8月4日召开第九届董事会第五次会议，审议 通过了《关于全资子公司增资的议案》。公司全资子公司张家港澳洋医院有限公司(简称"澳洋医院")， 拟以自有资金向其全资子公司张家港澳洋护理院有限公司(简称"澳洋护理院")增资，增资金额为人民币 1,700万元。本次增资完成后，澳洋护理院的注册资本由人民币500万元变更为人民币2,200万元。 ...

江苏澳洋健康产业股份有限公司 关于全资子公司增资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，并对公告的 虚假记载、误导性陈述或者重大遗漏负连带责任。 一、增资事项概述 二、增资对象的基本情况 关于全资子公司增资的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-24 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）于 2025 年 8 月 4 日召开第九届董事会第五次会议，审议通过了《关于全资子公司 增资的议案》。公司全资子公司张家港澳洋医院有限公司（以下简称"澳洋医院"）， 拟以自有资金向其全资子公司张家港澳洋护理院有限公司（以下简称"澳洋护理 院"）增资，增资金额为人民币 1,700 万元。本次增资完成后，澳洋护理院的注 册资本由人民币 500 万元变更为人民币 2,200 万元。 根据《深圳证券交易所股票上市规则》《公司章程》等相关规定，本次增资 事项属于公司董事会审议权限范围内，无需提交股东大会。本次增资事项不属于 关联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 11、最近一年及一期主要财务数据 1、公司名称：张家港澳洋护理院 ...